Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentivi...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Alton, E, Beekman, J, Boyd, A, Brand, J, Carlon, M, Connolly, M, Chan, M, Conlon, S, Davidson, H, Davies, J, Davies, L, Dekkers, J, Doherty, A, Gea-Sorli, S, Gill, D, Griesenbach, U, Hasegawa, M, Higgins, T, Hironaka, T, Hyndman, L, McLachlan, G, Inoue, M, Hyde, S, Innes, J, Maher, T, Moran, C, Meng, C, Paul-Smith, M, Pringle, I, Pytel, K, Rodriguez-Martinez, A, Schmidt, A, Stevenson, B, Sumner-Jones, S, Toshner, R, Tsugumine, S, Wasowicz, M, Zhu, J
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	BMJ Publishing Group 2016

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.

Παρόμοια τεκμήρια